The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.
May 14th 2024
These results may support clinical decision-making for psoriasis and nail psoriasis management and may allow future real-world studies to further understand the nature of this skin disease.
Secukinumab Reports Real-World Benefits, Tolerability in PROSPECT Trial
September 13th 2018Novartis reported that 59% of patients at 24 weeks experienced little to no impact of their condition on their quality of life. Additionally, 87% of bio-naïve psoriasis patients remained on secukinumab through 12 months, indicating its tolerability in real-world settings.
Managing Psoriatic Arthritis in Plaque Psoriasis Patients
Nearly one-third of patients with plaque psoriasis will also be diagnosed with psoriatic arthritis. While somewhat common, this diagnosis requires a different approach to care in order to help patients better manage their symptoms.
Diagnosing Plaque Psoriasis a 'Straightforward' Effort for Dermatologists
With plaque psoriasis becoming an increasingly common condition providers are able to more easily identify the condition than they had in the past. Looking for red scaling plaques, and thickened skin, as well as asking questions can get doctors the answers they need. In rare cases skin biopsies are also performed.
Developing New Treatments for Urticaria and Looking Toward the Future
For many patients, chronic idiopathic urticaria can be a debilitating condition affecting them at all hours of the day and making living with the condition very difficult. Because of this, the need for newer, more effective treatments is driving the field forward at a rapid pace.
Long-Term Secukinumab Treatment Safe and Effective for Patients with Psoriatic Arthritis
Patients with active psoriatic arthritis treated with secukinumab for 2 years in the FUTURE-1 trial experienced sustained decreases in disease activity and symptoms, leading to improvements in physical function and quality of life.
Study Endorses Early TNF Use in Patients with Psoriasis
A new model that combines real-world prices with outcome data from both controlled trials and clinical practice indicates that the immediate use of tumor necrosis factor inhibitors (anti-TNFs) is a cost-effective way to achieve good first-year outcomes in patients newly diagnosed with both plaque psoriasis and psoriatic arthritis.
Jerry Bagel: Discussing Treatment Options with Patients
As newer treatment options hit the market for plaque psoriasis patients may have more questions about the best options for them. This is part of the importance of communicating with patients throughout the treatment process.